Somatostatin receptor-targeted radionuclide therapy of tumors: Preclinical and clinical findingsMarion de Jong, Eric P. Krenning, François Jamar et al.|Seminars in Nuclear Medicine|2002Cited by 347
Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate.Roelf Valkema, Eric P. Krenning, Willem H. Bakker et al.|PubMed|2005Cited by 334
Survival and Response After Peptide Receptor Radionuclide Therapy With [90Y-DOTA0,Tyr3]Octreotide in Patients With Advanced Gastroenteropancreatic Neuroendocrine TumorsRoelf Valkema, Eric P. Krenning, François Jamar et al.|Seminars in Nuclear Medicine|2006Cited by 313